Sigilon Therapeutics, Inc.
SGTX · NASDAQ
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $20 | $41 | $42 | $33 |
| Short-Term Investments | $15 | $15 | $28 | $45 |
| Receivables | $7 | $5 | $3 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $3 | $3 | $1 | $2 |
| Total Curr. Assets | $45 | $65 | $74 | $81 |
| Property Plant & Equip (Net) | $10 | $11 | $12 | $13 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $1 | $1 | $1 | $1 |
| Total NC Assets | $11 | $12 | $13 | $14 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $56 | $77 | $87 | $95 |
| Liabilities | – | – | – | – |
| Payables | $1 | $1 | $1 | $1 |
| Short-Term Debt | $5 | $11 | $11 | $11 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $14 | $13 | $13 | $12 |
| Other Curr. Liab. | $6 | $4 | $6 | $6 |
| Total Curr. Liab. | $25 | $29 | $31 | $31 |
| LT Debt | $3 | $14 | $17 | $19 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $3 | $14 | $17 | $20 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $28 | $43 | $48 | $50 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$272 | -$264 | -$257 | -$250 |
| AOCI | -$0 | -$0 | -$0 | -$1 |
| Other Equity | $299 | $298 | $296 | $295 |
| Total Equity | $27 | $33 | $39 | $44 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $56 | $77 | $87 | $95 |
| Net Debt | -$12 | -$16 | -$14 | -$2 |